search
Back to results

Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive (DYVINE)

Primary Purpose

Myopathy, Muscular Weakness, Respiratory Insufficiency

Status
Unknown status
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
Bilevel pressure ventilator
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Myopathy focused on measuring Home ventilation, Myotonic dystrophy type 1 (DM1)

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Man or woman of age ≥ 18 years
  • Preliminary medical examination
  • Enlightened and written consent
  • Genetically proved Steinert disease

    1. Presenting at least one of the following 3 criteria

      • A hypercapnia: PaCO2 > 45 mmHg or
      • A night-desaturation: SaO2 < 88 % more than consecutive 5 minutes or
      • Apnea syndrome with significant sleep:index of apnea / hypopnea> a 30 / hour
    2. And with presence of at least a clinical sign: dyspnoea, orthopnea, headaches, asthenia, diurnal sleepiness, or any other sign suggestive of disturbance of the sleep or of respiratory dysfunction

Exclusion Criteria:

  • Age inferior to 18
  • Regime of legal protection
  • Pregnancy
  • Absolute indication for ventilation: clinical signs (dyspnoea, orthopnea, headaches, asthenia, diurnal sleepiness), AND PaCO2 > 60 mmHg, AND night-desaturation < 88 % AND one CV < 50 % of the theoretical or the PIMAX < 60 cm H2O
  • Acute respiratory failure
  • Already ventilated patient
  • Patient under oxygen
  • Not (beneficiary to a regime of Social Security or legal successor)

Sites / Locations

  • Home ventilation unit and intensive care, centre of neuromuscular disease (Garches Mondor Necker Hendaye), Raymond Poincaré hospital Versailles Saint Quentin University.

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

bipap ventilation

Standard care

Arm Description

Standard care and ventilation if occurrence of absolute criteria of ventilation (cf infra).

Outcomes

Primary Outcome Measures

Rate of patients having a complication (number of non expected hospitalization or death) at 5 years.
Rate of patients having a complication (number of non expected hospitalization or death) at 5 years.

Secondary Outcome Measures

Distribution of survival between the randomisation at 5 years
Distribution of survival between the randomisation at 5 years
Number of patients having a formal indication of ventilation
Number of patients having a formal indication of ventilation
Number of tracheostomized patients at 5 years
Number of tracheostomized patients at 5 years
Number of non expected hospitalizations at 5 years
Number of non expected hospitalizations at 5 years
Observance of the ventilation defined by an average minimal use of 4 am by 12:00 pm .
Observance of the ventilation defined by an average minimal use of 4 am by 12:00 pm (determined in a objective way by the counter of the device).
Degree of respiratory and sleep impairment at 5 years
Degree of respiratory and sleep impairment at 5 years
Quality of life SF36, scales of depression
Quality of life SF36, scales of depression

Full Information

First Posted
October 20, 2010
Last Updated
November 17, 2017
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Association Française contre les Myopathies (AFM), Paris
search

1. Study Identification

Unique Protocol Identification Number
NCT01225614
Brief Title
Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive
Acronym
DYVINE
Official Title
Study of Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive Ventilation in Adults With Myotonic Dystrophy Type 1(DM1)
Study Type
Interventional

2. Study Status

Record Verification Date
November 2017
Overall Recruitment Status
Unknown status
Study Start Date
October 2010 (Actual)
Primary Completion Date
July 2018 (Anticipated)
Study Completion Date
December 2018 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Association Française contre les Myopathies (AFM), Paris

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a multicenter randomized controlled open labeled study testing efficacy and tolerance of early launching of night non invasive ventilation in patients with myotonic dystrophy type 1(DM1). The object of this project is to estimate the effects of the early introduction of non invasive ventilation on the arisen of complication (non expected hospitalization, tracheostomy even death) with regard to a simple respiratory follow-up in patients affected by myotonic dystrophy.
Detailed Description
DM1 is the most frequent genetic myopathy in the adult. Actually there is no curative treatment, and symptomatic cares are essentials. The respiratory impairment is the main cause of morbid-mortality at these patients. The median of survival of the patients affected by DM1 with respiratory failure is of 59 years. Mechanisms of disease are complex implying a central and a direct impairment of respiratory muscles. These patients can present an alveolar hypoventilation, notably during night, not correlated to the muscular weakness. These patients often present a cognitive impairment complicating the interpretation of the clinical symptoms and their compliance to treatments. International recommendations for launching mechanical ventilation in neuromuscular diseases are the presence: 1) at least a clinical sign of alveolar hypoventilation, and one of the following criteria 2) diurnal hypercapnia (> 45 mmHg), 3) restrictive syndrome (vital capacity < 50 % and\or maximal inspiratory pressure < 60 cmH20), 4) the existence of a oxygen night-desaturation (SaO2 < 88 %) of more than 5 minutes. However, a Cochrane meta analyzes underline the absence of randomised study estimating the profit risk in the long term of the night-mechanical ventilation for progressive myopathies such as the DM1. The validity of these criteria and the effect of the ventilation on the survival and the complications were never estimated in DM1. On a retrospective series, the compliance is inferior and the observance is only 20 % a year and the incidence of the complications (death or resort to a tracheostomy) was 6 times as important in non observant patients. Objective (s) of the clinical study To estimate the efficiency and the tolerance of long term night-non invasive mechanical ventilation in patients affected by DM1. Main judgment criteria: Mortality and non programmed hospitalization. Experimental plan: Multicenter, national, randomized, controlled, study on 2 parallel groups. The subjects presenting a theoretical indication following consensual criteria of ventilation will be randomized either for a start up of ventilation or for an annual monitoring. Hypothesis: Early starting of non invasive ventilation allows a reduction of 20 % of the mortality or the number of non-programmed hospitalization compared to the control group for which the rate would be 40 %.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myopathy, Muscular Weakness, Respiratory Insufficiency
Keywords
Home ventilation, Myotonic dystrophy type 1 (DM1)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
77 (Actual)

8. Arms, Groups, and Interventions

Arm Title
bipap ventilation
Arm Type
Experimental
Arm Title
Standard care
Arm Type
Active Comparator
Arm Description
Standard care and ventilation if occurrence of absolute criteria of ventilation (cf infra).
Intervention Type
Device
Intervention Name(s)
Bilevel pressure ventilator
Intervention Description
Nocturnal home ventilation
Primary Outcome Measure Information:
Title
Rate of patients having a complication (number of non expected hospitalization or death) at 5 years.
Description
Rate of patients having a complication (number of non expected hospitalization or death) at 5 years.
Time Frame
5 YEARS
Secondary Outcome Measure Information:
Title
Distribution of survival between the randomisation at 5 years
Description
Distribution of survival between the randomisation at 5 years
Time Frame
5 YEARS
Title
Number of patients having a formal indication of ventilation
Description
Number of patients having a formal indication of ventilation
Time Frame
5 YEARS
Title
Number of tracheostomized patients at 5 years
Description
Number of tracheostomized patients at 5 years
Time Frame
5 YEARS
Title
Number of non expected hospitalizations at 5 years
Description
Number of non expected hospitalizations at 5 years
Time Frame
5 YEARS
Title
Observance of the ventilation defined by an average minimal use of 4 am by 12:00 pm .
Description
Observance of the ventilation defined by an average minimal use of 4 am by 12:00 pm (determined in a objective way by the counter of the device).
Time Frame
5 YEARS
Title
Degree of respiratory and sleep impairment at 5 years
Description
Degree of respiratory and sleep impairment at 5 years
Time Frame
5 YEARS
Title
Quality of life SF36, scales of depression
Description
Quality of life SF36, scales of depression
Time Frame
5 YEARS

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Man or woman of age ≥ 18 years Preliminary medical examination Enlightened and written consent Genetically proved Steinert disease Presenting at least one of the following 3 criteria A hypercapnia: PaCO2 > 45 mmHg or A night-desaturation: SaO2 < 88 % more than consecutive 5 minutes or Apnea syndrome with significant sleep:index of apnea / hypopnea> a 30 / hour And with presence of at least a clinical sign: dyspnoea, orthopnea, headaches, asthenia, diurnal sleepiness, or any other sign suggestive of disturbance of the sleep or of respiratory dysfunction Exclusion Criteria: Age inferior to 18 Regime of legal protection Pregnancy Absolute indication for ventilation: clinical signs (dyspnoea, orthopnea, headaches, asthenia, diurnal sleepiness), AND PaCO2 > 60 mmHg, AND night-desaturation < 88 % AND one CV < 50 % of the theoretical or the PIMAX < 60 cm H2O Acute respiratory failure Already ventilated patient Patient under oxygen Not (beneficiary to a regime of Social Security or legal successor)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
DAVID ORLIKOWSKI, MD, PhD
Organizational Affiliation
Assistance Publique - Hôpitaux de Paris
Official's Role
Principal Investigator
Facility Information:
Facility Name
Home ventilation unit and intensive care, centre of neuromuscular disease (Garches Mondor Necker Hendaye), Raymond Poincaré hospital Versailles Saint Quentin University.
City
Garches
ZIP/Postal Code
92380
Country
France

12. IPD Sharing Statement

Learn more about this trial

Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive

We'll reach out to this number within 24 hrs